Trial · NCT02512276
Tele-Pharmacy Intervention to Improve Treatment Adherence
NCT02512276, Not applicable, Completed, Brigham and Women's Hospital; results first posted 2019-06-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tele-Pharmacy Intervention to Improve Treatment Adherence. Trials, record NCT02512276. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02512276
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tele-Pharmacy Intervention to Improve Treatment Adherence
- NCT number
- NCT02512276
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 4,078 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Interventions
- Telepharmacist intervention
- First posted
- 2015-07-30
- Last updated
- 2019-06-06
- Results first posted
- 2019-06-06
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Medication Adherence | 12 months | Average proportion of days covered (PDC) for medications to treat eligible conditions. An eligible condition is a diagnosis of either hyperlipidemia, hypertension, or diabetes and evidence of poor control for that condition at the time of enrollment. Adherence will be measured as an average of averages PDC only for medications that qualified a patient for inclusion in the study. Medication adherence is often reported as percentage of days covered. |
| Secondary | Disease Control - All Eligible Conditions | 12 months | Percentage of patients achieving good disease control for all eligible conditions. Disease control was evaluated using laboratory or blood pressure values in the electronic health record and was based on clinical guideline targets (HbA1c values for patients with diabetes, systolic and diastolic blood pressure for patients with hypertension, and LDL values for patients with hyperlipidemia). This outcome measure disease control was measured as the proportion of patients achieving "good" disease control based on guideline-specified targets for all of their eligible conditions, as opposed to at least 1 for Outcome Measure 3. An eligible condition is a diagnosis of either hyperlipidemia, hypertension, or diabetes and evidence of poor control for that condition at the time of enrollment. |
| Secondary | Disease Control | 12 months | Percentage of patients achieving good disease control for at least one eligible condition. Disease control was evaluated using laboratory or blood pressure values in the electronic health record and was based on clinical guideline targets (HbA1c values for patients with diabetes, systolic and diastolic blood pressure for patients with hypertension, and LDL values for patients with hyperlipidemia). This outcome measure disease control was measured as the proportion of patients achieving "good" disease control based on guideline-specified targets for all at least 1 eligible condition, as opposed to all of their eligible conditions for Outcome Measure 2. An eligible condition is a diagnosis of either hyperlipidemia, hypertension, or diabetes and evidence of poor control for that condition at the time of enrollment. |
| Secondary | Healthcare Utilization - ER Visits | 12 months | Number of patients with at least 1 ER visit. |
| Secondary | Healthcare Utilization - Office Visits | 12 months | Number of patients with at least 1 office visit. |
| Secondary | Healthcare Utilization - Hospitalizations | 12 months | Number of patients with at least 1 hospitalization. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Medication Adherence | 12 months | Intention to treat | percentage of days covered | MEAN |
| SECONDARY | Disease Control - All Eligible Conditions | 12 months | Intention to treat | percentage of participants | NUMBER |
| SECONDARY | Disease Control | 12 months | Intention to treat | percentage of participants | NUMBER |
| SECONDARY | Healthcare Utilization - ER Visits | 12 months | Intention to treat | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Healthcare Utilization - Office Visits | 12 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Healthcare Utilization - Hospitalizations | 12 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Medication Adherence | Telepharmacist Intervention | 46.2 | Standard Deviation 33.9 | percentage of days covered | |
| Medication Adherence | Usual Care | 42.1 | Standard Deviation 33.8 | percentage of days covered | |
| Disease Control - All Eligible Conditions | Telepharmacist Intervention | 67.4 | percentage of participants | ||
| Disease Control - All Eligible Conditions | Usual Care | 66.2 | percentage of participants | ||
| Disease Control | Telepharmacist Intervention | 72.9 | percentage of participants | ||
| Disease Control | Usual Care | 71.2 | percentage of participants | ||
| Healthcare Utilization - ER Visits | Telepharmacist Intervention | 90 | Participants | ||
| Healthcare Utilization - ER Visits | Usual Care | 113 | Participants | ||
| Healthcare Utilization - Office Visits | Telepharmacist Intervention | 641 | Participants | ||
| Healthcare Utilization - Office Visits | Usual Care | 594 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Telepharmacist Intervention | 2,038 | |
| Overall Study | STARTED | Usual Care | 2,040 | |
| Overall Study | COMPLETED | Telepharmacist Intervention | 2,030 | |
| Overall Study | COMPLETED | Usual Care | 2,029 | |
| Overall Study | NOT COMPLETED | Telepharmacist Intervention | 8 | |
| Overall Study | NOT COMPLETED | Usual Care | 11 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Telepharmacist Intervention | 0 | 0 |
| Total, all-cause mortality | Usual Care | 0 | 0 |
| Total, other adverse events | Telepharmacist Intervention | 0 | 0 |
| Total, other adverse events | Usual Care | 0 | 0 |
| Total, serious adverse events | Telepharmacist Intervention | 0 | 0 |
| Total, serious adverse events | Usual Care | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30083727 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Telepharmacist Intervention vs Usual Care: Healthcare Utilization - Hospitalizations | Trial comparisons |
| Telepharmacist Intervention vs Usual Care: Healthcare Utilization - ER Visits | Trial comparisons |
| Telepharmacist Intervention vs Usual Care: Healthcare Utilization - Office Visits | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02512276
GET https://conductscience.org/api/trials/v1/NCT02512276/registered